![Thomas F. White](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas F. White
Keine laufenden Positionen mehr
Karriereverlauf von Thomas F. White
Ehemalige bekannte Positionen von Thomas F. White
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Weider Nutrition International, Inc. | Corporate Officer/Principal | - | - |
Shaman Pharmaceuticals, Inc.
![]() Shaman Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shaman Pharmaceuticals, Inc. engages in the discovery, development, and marketing of novel, proprietary botanical dietary supplements from tropical plant sources. The company was founded by Lisa A. Conte in May 1989 and is headquartered in San Francisco, CA. | Vertrieb & Marketing | 17.03.2010 | - |
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Gründer | 01.10.2002 | - |
Präsident | 01.10.2002 | - |
Statistik
International
Vereinigte Staaten | 4 |
Operativ
Founder | 1 |
President | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 3 |
Consumer Non-Durables | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
BiPar Sciences, Inc.
![]() BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
Weider Nutrition International, Inc. | Consumer Non-Durables |
Shaman Pharmaceuticals, Inc.
![]() Shaman Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Shaman Pharmaceuticals, Inc. engages in the discovery, development, and marketing of novel, proprietary botanical dietary supplements from tropical plant sources. The company was founded by Lisa A. Conte in May 1989 and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Thomas F. White
- Erfahrung